parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in schwann cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	7 Parkinson's papers of 650	0.73
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 7106

NFATC2 in dopamine neurons, braak-0.24 (p 0.535) → -0.30 (p 0.428)receipt 7114
NFATC2 in microglia, braak-0.42 (p 0.258) → +0.39 (p 0.304)receipt 7113

receipt 7114: NFATC2 in dopamine neurons, braak

power: full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.360, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.161, n 18). could be the mix.
skeptic: leave-one-out range -0.36 to -0.13, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NFATC2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7113: NFATC2 in microglia, braak

power: full sample +0.01 (p 0.956, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.03 (p 0.915, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.03 (p 0.915, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.15, sign flips 7; without severely affected donors +0.01 (p 0.956, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NFATC2 in microglia.

case closed: nothing better to follow up.

loading the receipts